e-therapeutics plc is an Oxford, UK-based company with a powerful computer-based approach to drug discovery, founded on its industry-leading expertise in network biology to fully capture disease complexity. The Company combines network science, machine learning, artificial intelligence, statistics and big data with expertise in drug discovery and development to transform the search for new medicines and intervention strategies.
e-therapeutics has developed an in silico laboratory that enables the rapid screening of millions of compounds and the identification of small subsets that are enriched for highly active hits. Its proprietary platform also has novel applications in functional genomics, being able to analyse complex genetic datasets, provide a deep understanding of pathological mechanisms and distil actionable insights for the discovery of novel drugs, biomarkers and diagnostics.
e-therapeutics has deployed and validated its disease-agnostic drug discovery platform both in house and with partners, including Novo Nordisk, Galapagos NV and a US-based, top 5 pharmaceutical company.
Directors and committees
Details of e-therapeutics’ Board of Directors, including biographical information is available here.
A description of the responsibilities of the Directors and details of Board committees and their responsibilities is available here.
Country of incorporation and main country of operation
e-therapeutics plc is incorporated in England and Wales. Its main country of operation is the UK.
Current constitutional documents
The Company’s articles of association are available here.
Securities in issue
Details of the number of AIM securities in issue, the percentage of AIM securities that is not in public hands and the identity and percentage holdings of its significant shareholders are available here.
Annual accounts and interim reports
Copies of the Company’s annual reports and interim financial statements may be accessed here.
Notifications, admission document and circulars
Click on the links below for access to the following documents:
- all regulatory announcements issued in the last five years
- circulars, notifications or similar publications sent to shareholders by the Company in the last five years
- the most recent admission document
Details of the Company’s corporate governance arrangements are available here.
The Company is subject to the UK City Code on Takeovers and Mergers.
Details of the Company’s nominated advisor and other key advisors may be found here.